Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Not Measuring Residual Gastric Volume on Nosocomial Pneumonia Rates in Mechanically Ventilated Patients Receiving Early Enteral Feeding: a Randomized-controlled Study
Brief Summary: Early enteral feeding is a key component of the management of critically ill patients receiving mechanical ventilation. However, enteral feeding has been associated with serious complications such as aspiration followed by ventilator-associated pneumonia (VAP). Many critically ill patients experience poor tolerance of early enteral nutrition because of impaired gastric motility, which leads to a sequence of delayed gastric emptying, increased gastric volume, gastroesophageal reflux, vomiting, aspiration, and VAP. Routine monitoring of residual gastric volume (RGV) to minimize the risk of aspiration is standard practice. RGV is assumed to reflect gastric content, with high RGVs indicating impaired gastric emptying that requires discontinuation of enteral feeding in order to prevent aspiration.However, RGV measurement is neither standardized nor validated. The cut-off value that may indicate an increased risk of aspiration and therefore a need for discontinuing enteral feeding has not been determined, and cut-offs used in studies have ranged from 150 to 500 ml. No data are available to support a correlation between RGV and the rates of adverse events. In experimental studies, RGV failed to correlate with vomiting, aspiration, or VAP. The investigators hypothesize that RGV monitoring fails to decrease the risk of VAP and leed to inappropriate interruptions in enteral feeding with a risk of underfeeding. To assess the effects of not measuring RGV on VAP and enteral feeding delivery, the investigators designed a prospective randomized controlled study.


Options:
A: Arm Label: povidone iodine; Type: EXPERIMENTAL; Interventions: Drug: povidone iodine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: povidone iodine; Assigned to Arm(s): povidone iodine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: residual gastric volume; Type: OTHER; Interventions: Procedure: monitoring of residual gastric volume | Arm Label: residual gastric volume not monitored; Type: OTHER; Interventions: Procedure: not monitoring of residual gastric volume | Intervention Type: PROCEDURE; Name: monitoring of residual gastric volume; Assigned to Arm(s): residual gastric volume | Intervention Type: PROCEDURE; Name: not monitoring of residual gastric volume; Assigned to Arm(s): residual gastric volume not monitored
C: Intervention Type: PROCEDURE; Name: Reinforced isolation + Muciprocine; Assigned to Arm(s): N/A
D: Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine oral care (CHX-Oro), Drug: Selective oropharyngeal decontamination (SOD), Drug: Selective Digestive Decontamination (SDD) | Arm Label: Chlorhexidine oral care (CHX-Oro); Type: EXPERIMENTAL; Interventions: Drug: Chlorhexidine oral care (CHX-Oro) | Arm Label: Selective oropharyngeal decontamination; Type: EXPERIMENTAL; Interventions: Drug: Selective oropharyngeal decontamination (SOD) | Arm Label: Selective digestive decontamination; Type: EXPERIMENTAL; Interventions: Drug: Selective Digestive Decontamination (SDD) | Intervention Type: DRUG; Name: Chlorhexidine oral care (CHX-Oro); Assigned to Arm(s): Chlorhexidine oral care (CHX-Oro), Standard care | Intervention Type: DRUG; Name: Selective oropharyngeal decontamination (SOD); Assigned to Arm(s): Selective oropharyngeal decontamination, Standard care | Intervention Type: DRUG; Name: Selective Digestive Decontamination (SDD); Assigned to Arm(s): Selective digestive decontamination, Standard care

Answer: B